Article
Endocrinology & Metabolism
Jinqian Mao, Jin Hu, Yanting Zhang, Jian Shen, Fang Dong, Ximeng Zhang, Jie Ming, Tao Huang, Xiaoqin Run
Summary: This study compared single hormone receptor-positive breast cancer to other subtypes and found clinically and biologically distinct features. The prognosis of single hormone receptor-positive tumors was similar to hormone receptor-negative and hormone receptor-positive tumors in patients with or without HER2 overexpression.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Genetics & Heredity
Justine Marsolier, Pacome Prompsy, Adeline Durand, Anne-Marie Lyne, Camille Landragin, Amandine Trouchet, Sabrina Tenreira Bento, Almut Eisele, Sophie Foulon, Lea Baudre, Kevin Grosselin, Mylene Bohec, Sylvain Baulande, Ahmed Dahmani, Laura Sourd, Eric Letouze, Anne-Vincent Salomon, Elisabetta Marangoni, Leila Perie, Celine Vallot
Summary: The persistence of drug-resistant cancer cells is a major clinical challenge, particularly in triple-negative breast cancer. This study reveals that the repressive histone mark H3K27me3 plays a crucial role in regulating cell fate and chemotherapy tolerance in cancer cells. Manipulating H3K27me3 levels effectively enhances the potential of cancer cells to tolerate chemotherapy and delays tumor recurrence. These findings underscore the importance of understanding chromatin landscapes in shaping cancer cell response to initial therapy.
Article
Biochemistry & Molecular Biology
Lake-Ee Quek, Michelle van Geldermalsen, Yi Fang Guan, Kanu Wahi, Chelsea Mayoh, Seher Balaban, Angel Pang, Qian Wang, Mark J. Cowley, Kristin K. Brown, Nigel Turner, Andrew J. Hoy, Jeff Holst
Summary: This study reveals that glutamine-indispensable triple-negative breast cancer (TNBC) cells rely on a non-canonical glutamine-to-glutamate overflow, which increases TCA cycle fluxes and replenishes TCA cycle intermediates. The coupling of glucose and glutamine catabolism hampers TNBC cells' ability to oxidize glucose when glutamine is limiting.
Review
Oncology
Dorota Kwapisz
Summary: Triple-negative breast cancer (TNBC) is a subtype of breast cancer with poor prognosis and limited treatment options, but it shows higher immunogenicity, tumor-infiltrating lymphocytes (TILs) enrichment, and programmed cell death ligand 1 (PD-L1) expression which make it more suitable for immune checkpoint blockade therapy. Patients with PD-L1-positive TNBC subgroup may benefit the most from immune checkpoint inhibitor (ICI) treatment, and ICI given as first-line treatment in advanced TNBC shows better results than in later lines of treatment. Exciting results have been seen with pembrolizumab in early-stage TNBC, indicating potential approval in (neo)adjuvant settings in the near future.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2021)
Article
Surgery
Yuping Tan, Biao Yang, Yuhong Chen, Xi Yan
Summary: This study compares the survival outcomes of metaplastic breast cancer (MPBC) with triple-negative breast cancer (TNBC) and identifies prognostic factors for both types of cancer. The study finds that MPBC is associated with worse overall survival (OS) and disease-free survival (DFS) compared to TNBC. Additionally, within the MPBC group, the subtype with mesenchymal differentiation has a worse DFS compared to other subtypes.
WORLD JOURNAL OF SURGERY
(2023)
Letter
Medicine, General & Internal
Ryan Sun, Lee-Jen Wei
Summary: This article discusses the clinical benefits of pembrolizumab combined with chemotherapy in patients with triple-negative breast cancer. The authors suggest that both hazard values and ratios should be considered when evaluating clinical benefits.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Chemistry, Medicinal
Carine M. Abdelmalek, Zexi Hu, Thales Kronenberger, Jenni Kublbeck, Franziska J. M. Kinnen, Salma S. Hesse, Afsin Malik, Mark Kudolo, Raimund Niess, Matthias Gehringer, Lars Zender, Paula A. Witt-Enderby, Darius P. Zlotos, Stefan A. Laufer
Summary: Anticancer drug conjugates that simultaneously target two receptors may overcome the limitations of current cancer treatments. A series of compounds connecting tamoxifen or endoxifen with the EGFR-inhibitor gefitinib exhibit potent anticancer activity in breast cancer cells.
JOURNAL OF MEDICINAL CHEMISTRY
(2022)
Article
Oncology
Rui Han, Hongxing Yang, Changquan Ling, Lingeng Lu
Summary: In this study, the therapeutic potential of Tiliroside (TS) in triple negative breast cancer (TNBC) was evaluated. The results showed that TS exhibited anti-cancer activity, reduced tumor burden, and improved survival rate in TNBC. Additionally, TS acted as a CAXII inhibitor to suppress TNBC progression.
CANCER CELL INTERNATIONAL
(2022)
Article
Oncology
Kurt W. Evans, Erkan Yuca, Stephen S. Scott, Ming Zhao, Natalia Paez Arango, Christian X. Cruz Pico, Turcin Saridogan, Maryam Shariati, Caleb A. Class, Christopher A. Bristow, Christopher P. Vellano, Xiaofeng Zheng, Ana Maria Gonzalez-Angulo, Xiaoping Su, Coya Tapia, Ken Chen, Argun Akcakanat, Bora Lim, Debu Tripathy, Timothy A. Yap, Maria Emilia Di Francesco, Giulio F. Draetta, Philip Jones, Timothy P. Heffernan, Joseph R. Marszalek, Funda Meric-Bernstam
Summary: Oxidative phosphorylation is a metabolic vulnerability in triple-negative breast cancer, and inhibiting it with IACS-10759 may enhance efficacy of multiple targeted therapies.
Review
Oncology
Shengye Jin, Qin Wang, Hao Wu, Da Pang, Shouping Xu
Summary: Biological therapy, particularly oncolytic viruses (OVs), has shown promising therapeutic effects in various cancers, including triple negative breast cancer (TNBC). TNBC, lacking conventional treatment targets, benefits from the emerging concept of OVs for potential treatment options.
BIOMARKER RESEARCH
(2021)
Review
Medicine, General & Internal
Jieun Lee
Summary: Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer, accounting for 15-20% of cases, with a high rate of recurrence despite chemotherapy. Conventional cytotoxic chemotherapy with anthracyclines and taxanes remains the main treatment option. Achievement of pathologic complete response (pCR) is associated with improved survival outcomes, leading to the shift towards neoadjuvant treatment and investigation of intensified chemotherapy and post-neoadjuvant therapy. This article reviews the current treatment landscape for early TNBC, from standard cytotoxic chemotherapy to immune checkpoint inhibitors, capecitabine, and olaparib.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Cell Biology
Giulia Salvadori, Federica Zanardi, Fabio Iannelli, Riccardo Lobefaro, Claudio Vernieri, Valter D. Longo
Summary: The study demonstrates that a fasting-mimicking diet activates starvation escape pathways in TNBC cells and reduces stemness markers in CSCs, leading to decreased cell numbers and improved mouse survival. Additionally, the diet activates different survival/growth pathways in differentiated cancer cells, which can be targeted by drugs to promote tumor regression.
Letter
Medicine, General & Internal
Shuvadeep Ganguly, Ajay Gogia
Summary: In the KEYNOTE-522 trial, the addition of Pembrolizumab to neoadjuvant chemotherapy improved pathological complete response rate in early triple-negative breast cancer patients and also improved event-free survival. However, this improvement was predominantly observed in patients who did not achieve a pathological complete response.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Jankiben R. Patel, Prasad Thangavelu, Renee M. Terrell, Bridg'ette Israel, Arindam Basu Sarkar, A. Michael Davidson, Kun Zhang, Rahul Khupse, Syreeta L. Tilghman
Summary: A novel allosteric inhibitor targeting the PLK1 T-loop was developed and shown to have anti-proliferative and anti-migratory properties in triple-negative breast cancer cells. The inhibitor caused cell cycle arrest and increased p21 expression, suggesting its potential as a promising approach for TNBC treatment.
Article
Oncology
Felipe Batalini, Niya Xiong, Nabihah Tayob, Madeline Polak, Julia Eismann, Lewis C. Cantley, Geoffrey Shapiro, Viktor Adalsteinsson, Eric P. Winer, Panagiotis A. Konstantinopoulos, Alan D'Andrea, Elizabeth M. Swisher, Ursula A. Matulonis, Gerburg M. Wulf, Erica L. Mayer
Summary: This study aimed to evaluate the safety and recommended dose of olaparib in combination with alpelisib in patients with breast cancer, and explore its effects on different subtypes. The results showed that this combination therapy was tolerable for pre-treated TNBC patients and demonstrated activity in non-BRCA mutant patients. Analysis of circulating-free DNA also provided important prognostic information.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Ming Shen Dai, Yin Hsun Feng, Shang Wen Chen, Norikazu Masuda, Thomas Yau, Shou Tung Chen, Yen Shen Lu, Yoon Sim Yap, Peter C. S. Ang, Sung Chao Chu, Ava Kwong, Keun Seok Lee, Samuel Ow, Sung Bae Kim, Johnson Lin, Hyun Cheol Chung, Roger Ngan, Victor C. Kok, Kun Ming Rau, Takafumi Sangai, Ting Ying Ng, Ling Ming Tseng, Richard Bryce, Judith Bebchuk, Mei Chieh Chen, Ming Feng Hou
Summary: In this study, neratinib plus capecitabine showed extended progression-free survival and overall survival in Asian patients with HER2+ metastatic breast cancer who had received >= 2 HER2-directed regimens, with manageable adverse effects. No new safety concerns were identified.
BREAST CANCER RESEARCH AND TREATMENT
(2021)
Review
Oncology
Yen-Shen Lu, Andrea Wong, Hee-Jeong Kim
Summary: Combining ovarian function suppression (OFS) with endocrine therapy has been shown to significantly increase survival rates in some premenopausal patients with HR+ breast cancer, providing a new potential treatment option.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Ching-Hung Lin, Ruby Yun-Ju Huang, Tzu-Pin Lu, Kuan-Ting Kuo, Ko-Yun Lo, Ching-Hsuan Chen, I-Chun Chen, Yen-Shen Lu, Eric Y. Chuang, Jean Paul Thiery, Chiun-Sheng Huang, Ann-Lii Cheng
Summary: The incidence of breast cancer among women under 50 years old in East Asia has been rapidly increasing, with unique genetic alterations identified in these tumors such as copy number loss in the APOA1/C3/A4/A5 gene cluster. This genetic change may have immunomodulatory effects on the tumor microenvironment and play various roles in the tumor biology of East Asian patients.
Article
Oncology
Po-Han Lin, Shin-Cheh Chen, Ling-Ming Tseng, King-Jen Chang, Ai-Chu Huang, Kuo-Chih Cheng, Karen Yang, Hui-Chen Wu, Tsu-Yi Chao, Yuan-Ching Chang, Peng-Chan Lin, Wen-Hung Kuo, Wen-Lin Kuo, Ching-Hung Lin, Huo-Mu Chen, Dah-Cherng Yeh, Liang-Chih Liu, Chun-Yu Liu, Ming-Yang Wang, Chiao Lo, Yen-Shen Lu, Chiun-Sheng Huang
Summary: The study found that Asian breast cancer patients with BRCA mutations had a higher risk of developing contralateral breast cancer, especially for BRCA1 mutation carriers with triple-negative breast cancer as their first breast cancer. However, there were no significant differences in relapse-free survival and overall survival between mutation carriers and control patients.
BREAST CANCER RESEARCH AND TREATMENT
(2022)
Article
Oncology
Sherko Kuemmel, Mario Campone, Delphine Loirat, Rafael Lopez Lopez, J. Thaddeus Beck, Michelino De Laurentiis, Seock-Ah Im, Sung-Bae Kim, Ava Kwong, Guenther G. Steger, Esther Zamora Adelantado, Francois P. Duhoux, Richard Greil, Irene Kuter, Yen-Shen Lu, Ariadna Tibau, Mustafa Ozguroglu, Christian W. Scholz, Christian F. Singer, Estela Vega, Pauline Wimberger, Claudio Zamagni, Xuan-Mai Couillebault, Liqiong Fan, Nelson Guerreiro, Jennifer Mataraza, Janna Sand-Dejmek, Arlene Chan
Summary: This phase II study aimed to evaluate the efficacy of lacnotuzumab added to gemcitabine plus carboplatin in patients with advanced triple-negative breast cancer. The results showed that lacnotuzumab + gem-carbo had comparable antitumor activity to gem-carbo alone, but with slightly poorer tolerability.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Yen-Shen Lu, Seock-Ah Im, Marco Colleoni, Fabio Franke, Aditya Bardia, Fatima Cardoso, Nadia Harbeck, Sara Hurvitz, Louis Chow, Joohyuk Sohn, Keun Seok Lee, Saul Campos-Gomez, Rafael Villanueva Vazquez, Kyung Hae Jung, K. Govind Babu, Paul Wheatley-Price, Michelino De Laurentiis, Young-Hyuck Im, Sherko Kuemmel, Nagi El-Saghir, Ruth O'Regan, Claudia Gasch, Nadia Solovieff, Craig Wang, Yongyu Wang, Arunava Chakravartty, Yan Ji, Debu Tripathy
Summary: Ribociclib plus endocrine therapy has been shown to significantly improve the progression-free survival and overall survival of pre-/perimenopausal patients with advanced breast cancer.
CLINICAL CANCER RESEARCH
(2022)
Article
Medicine, General & Internal
Ryan Shea Ying Cong Tan, Whee Sze Ong, Kyung-Hun Lee, Abner Herbert Lim, Seri Park, Yeon Hee Park, Ching-Hung Lin, Yen-Shen Lu, Makiko Ono, Takayuki Ueno, Yoichi Naito, Tatsuya Onishi, Geok-Hoon Lim, Su-Ming Tan, Han-Byoel Lee, Han Suk Ryu, Wonshik Han, Veronique Kiak Mien Tan, Fuh-Yong Wong, Seock-Ah Im, Puay Hoon Tan, Jason Yongsheng Chan, Yoon-Sim Yap
Summary: This study evaluated the impact of low expression of HER2 on survival outcomes in HER2-negative non-metastatic breast cancer (BC). The results showed that HER2-low BC had a superior prognosis compared to HER2-zero BC in the non-metastatic setting, though the absolute differences were modest and driven by HER2 IHC 1+ BC. Further investigation is needed for the ERBB2 CNV status in HER2-negative BC.
Article
Oncology
Wei-Li Ma, Dwan-Ying Chang, Ching-Hung Lin, Kao-Lang Liu, Po-Chin Liang, Huang-Chun Lien, Chan-Chuan Hu, Ling-Yun Huang, Yi-Chun Yeh, Yen-Shen Lu
Summary: Pseudocirrhosis is a common finding in liver metastasis, and its presence can lead to a shorter overall survival in patients with metastatic breast cancer. The presence of esophageal or gastric varices is associated with poorer outcomes in these patients.
Article
Oncology
Ching-Hung Lin, Muhammad Zahid, Wen-Hung Kuo, Ming-Yang Wang, Fu-Chang Hu, I-Chun Chen, Cheryl L. Beseler, Bodhisattwa Mondal, Yen -Shen Lu, Eleanor G. Rogan, Ann-Lii Cheng
Summary: The incidence of breast cancer among premenopausal women in East Asia has been increasing rapidly. This study found that the ratio of estrogen-DNA adducts in plasma was significantly higher in the case group compared to the control group, and it was a significant predictor of breast cancer risk in premenopausal women.
CANCER PREVENTION RESEARCH
(2023)
Review
Oncology
Shang-Hsuan Peng, Ching-Hung Lin, I-Chun Chen, Ying-Chun Shen, Dwan-Ying Chang, Tom Wei-Wu Chen, Shu-Min Huang, Fu-Chang Hu, Yen-Shen Lu
Summary: This systematic review found that Asian patients with advanced cancers may derive superior overall survival benefits from pembrolizumab compared to non-Asian patients. However, no significant difference was found in progression-free survival. The study also identified the open-label design as a key covariate that favored non-Asian participants. These findings provide important insights into clinical research design.
Article
Oncology
Ming-Shen Dai, Ta-Chung Chao, Chang-Fang Chiu, Yen-Shen Lu, Her-Shyong Shiah, Christopher G. C. A. Jackson, Noelyn Hung, Jianguo Zhi, David L. L. Cutler, Rudolf Kwan, Douglas Kramer, Wing-Kai Chan, Albert Qin, Kuan-Chiao Tseng, Cheung Tak Hung, Tsu-Yi Chao
Summary: This study investigated the pharmacokinetics, overall response rate, and safety of weekly oral paclitaxel with encequidar in patients with advanced breast cancer. The results showed that the combination therapy produced consistent therapeutic plasma paclitaxel exposure and had a high clinical benefit rate, with a low rate of neurotoxicity.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2023)
Article
Immunology
I-Chun Chen, Deepika Awasthi, Chia-Lang Hsu, Minkyung Song, Chang-Suk Chae, Andrew J. Dannenberg, Juan R. Cubillos-Ruiz
Summary: Obesity caused by high-fat diet disrupts the metabolic and functional status of splenic dendritic cells (SpDCs), leading to severe changes in gene expression. SpDCs from obese mice demonstrate enhanced mitochondrial respiration and reactive oxygen species accumulation, impairing antigen presentation to T cells. The use of FAO inhibitors and antioxidants can restore the antigen-presenting capacity of SpDCs from obese mice.
JOURNAL OF IMMUNOLOGY
(2022)
Article
Oncology
Peter Schmid, Marie-Paule Sablin, Jonas Bergh, Seock-Ah Im, Yen-Shen Lu, Noelia Martinez, Patrick Neven, Keun Seok Lee, Serafin Morales, J. Alejandro Perez-Fidalgo, Douglas Adamson, Anthony Goncalves, Aleix Prat, Guy Jerusalem, Laura Schlieker, Rosa-Maria Espadero, Thomas Bogenrieder, Dennis Chin-Lun Huang, John Crown, Javier Cortes
Summary: The study evaluated the efficacy of using xentuzumab in combination with everolimus and exemestane in patients with hormone receptor-positive breast cancer. While no improvement in PFS was seen in the overall population, there was evidence of benefit in patients without visceral metastases.
BREAST CANCER RESEARCH
(2021)
